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As the authors note, the familywise error rate (FWER) is used rather often, whereas the
per-family error rate (PFER) is not. Is this as it should be? It would seem that no
universal answer is possible, as context determines which is more appropriate in any
given application. In the general scenario of testing the benefit of an intervention, one
might ideally want an error rate that aligns with the decision for benefit. In most cases the
FWER does this pretty well, while allowing one to identify those endpoints for which
benefit exists. The PFER does not seem to have any advantage over the FWER in this
general testing scenario. Perhaps in some other scenarios the PFER might have some
reasonable role.
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Introduction
As Berger (2004) notes, the alpha level should be selected strategically, based on
the ramifications of committing a Type I error relative to a Type II error. The
entire testing framework becomes more complicated when dealing with multiple
hypothesis tests, and in this case various circumstances must be taken into
account. Apart from choosing the proper alpha level for the specific situation, one
must also define (prospectively) what constitutes a win (so to speak). Is it enough
to find statistical significance on any one endpoint? Or do we instead combine the
results in some way to obtain an overall finding?
The familywise Type-I error rate (FWER) is the probability of at least one
Type I error in a family of hypotheses occurring, and is used rather often. The
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per-family Type I error rate (PFER) is the sum of probabilities of Type I errors in
the family for all hypotheses, and is almost never used in practice (Frane, 2015).
When performing multiple hypothesis tests, various circumstances must be
taken into account. Apart from choosing the proper alpha level for the specific
situation (preferably strategically, rather than based on the one size fits all
precedent of 0.05), there is a risk that a Type I (false positive) or Type II (false
negative) error may occur. The familywise Type-I error rate (FWER), the
probability of at least one Type I error in a family of hypotheses occurring, is used
rather often. Meanwhile, the per-family Type I error rate (PFER), the sum of
probabilities of Type I errors in the family for all hypotheses, is almost
completely ignored (Frane, 2015). Does the PFER deserve as much attention as
the FWER receives? We do not attempt any general answer to this question, but,
instead, focus on one specific application. For the commonly encountered
scenario of testing the benefit of an intervention with several possible endpoints,
we think there is a good reason why PFER is not used.
As the author (Frane, 2015) states, committing numerous Type I errors
simultaneously is worse than committing only one, with FWER unable to
differentiate between creating one Type I error and multiple Type I errors in a
family of hypotheses. We suggest that the choice between controlling the FWER
or the PFER should be based on the specific situation. The FWER works well for
the commonly encountered scenario of testing an intervention with several
possible endpoints of interest. The PFER does not appear to have any advantage
over the FWER in this scenario, but perhaps in some other scenarios it might. The
purpose of this response is not to determine which error rate is superior to the
other, but how to establish which error rate should be controlled based on a
testing situation. We first consider the scenario of testing an intervention for
benefit due to any of several endpoints and then discuss the choice of alpha level.

Tests of an intervention with multiple endpoints of interest
Consider a study designed to test whether an intervention or exposure is beneficial
or detrimental to patient health, compared to some comparison condition. Suppose
that benefit can be measured by using any of several endpoints. This is quite a
general scenario, which applies equally to clinical trials as well as to behavioral
intervention studies or in fact to many observational studies. In this case, it is easy
to see that control of the FWER is sufficient to guarantee that if any endpoint is
identified as significant, and if biases can be suitably removed by the study design,
then either any such endpoint is truly affected by the intervention or an unlikely
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event has occurred. This is also true if the PFER is controlled. However, control
of the PFER is more restrictive (less powerful) than control of the FWER. Thus,
there is no reason to prefer the PFER to the FWER in this general scenario.
An interesting observation about this scenario is that control of the FWER is
not necessary to guarantee the type of concordance desired. One might consider
testing an intersection hypothesis whose rejection corresponds with evidence of
an intervention benefit. To make this clearer, suppose that there are two endpoints,
and let H1 (H2) be the null hypothesis that the first (second) endpoint is unaffected
by the intervention. If one would recommend the intervention if either endpoint is
beneficial, then one really wants to claim benefit if either H 1 or H2 are false. This
argues for testing the intersection null hypothesis H 0 = H1 ∩ H2 . Rejection of this
null hypothesis corresponds to benefit. This approach circumvents multiple
comparison altogether as only a single hypothesis is tested.
The downside to this approach is that rejection of H 0 leaves one unable to
conclude improvement on any specific endpoint. As Durkalski and Berger (2009)
note, success on a composite endpoint leaves one “unable to determine which
outcome is driving the claim”. The other caveat to this approach is one must
decide how to test H0 , which in general could be difficult. An adaptive testing
approach could prove useful (Berger and Ivanova, 2002), but the usual solution
for testing H0 involves rejecting if min(p1, p2) ≤ α/2, where p1 (p2) is the p-value
for testing H 1 (H2). With this solution, one is once again controlling the FWER,
although in general such an approach could lead to more powerful testing
procedures. This observation is a major reason why FWER is the predominantly
used error rate for publications of confirmatory findings for studies that test an
intervention. Bloch et al. (2001) describe one way of testing a single null
hypothesis, although rejecting their null also allows one to conclude noninferiority on all endpoints.
Choosing an alpha level
Returning now to the strategic selection of the alpha level, we note that
cancer therapy often involves both high risk and high reward. The promise of
meaningful improvement is counterbalanced by the almost certain toxicity of the
treatment which, in some cases, may have the potential to do more harm than
good. That said, false positives and false negatives can both result in grave
consequences, including illnesses left untreated, illnesses over-treated, and
ultimately higher mortality rates for patients. So the calculation has to consider
the relative harm likely caused by each type of error.
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As one extreme example (following Berger, 2004), one may conduct a trial
to determine if broccoli will prevent arthritis. If broccoli is found, rightfully or
wrongfully, to prevent arthritis, then the result would simply be increased
consumption of broccoli. Since broccoli is known to have other health benefits,
and few (if any) drawbacks, this will still lead to substantial health benefits,
regardless if it helps to treat the symptoms of arthritis. So here, a Type I error
would not result in very much harm at all. Alpha can be set to a much larger level
than the usual 0.05. Another example is Glucosamine and Chondroitin. Like
broccoli, these substances have no known side effects and are known to be
generally good for cartilage health. Despite no strong evidence of a benefit for
sufferers of osteoarthritis pain, many people take Glucosamine and Chondroitin
because of the low risk involved coupled with some possible benefit. Conversely,
if an aggressive and highly toxic cancer treatment is found to be beneficial, then
its increased use will incur additional costs and also result in toxicity, so the
benefit should offset this risk, and we should be fairly certain that it does (Berger,
2004). A Type I error in this case would result in severe consequences, so alpha
should be small, 0.05 or perhaps even 0.01. These are simple examples, but the
concept is that alpha should be carefully considered, and not just set at the usual
level of 0.05 as a matter of course (Berger & Hsieh, 2005).
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